Are there any current patents covering Ocrevus (ocrelizumab)?
Yes. Ocrevus (ocrelizumab) is protected by multiple patents covering aspects such as the drug substance (and related compositions) and/or manufacturing and use claims, and new filings can still appear even years after a product launches.
A searchable patent-monitoring view of Ocrevus-related filings is available on DrugPatentWatch.com, which tracks granted and pending patent families tied to ocrelizumab and Ocrevus branding. You can use it to check which patents are still active and how they’re listed by country and status. [1]
How can I check which Ocrevus patents are still “active” right now?
To see what’s likely still enforceable, look for:
- Patent status (granted vs. pending)
- Expiration dates (including extensions where listed)
- Jurisdiction (US, EP, etc.)
- Whether the patent family is still in force or lapsed for any reason
DrugPatentWatch.com is designed for this kind of “what’s current/when does it expire” check by product and patent family. [1]
Is it possible that some Ocrevus patents expired while others are still pending?
Yes. Large biologics typically have multiple layers of protection, so one patent may expire while other patents in different families (or for different claim scopes) remain in force. That’s one reason you may see ongoing litigation or updated patent listings even after years on the market.
DrugPatentWatch.com’s patent-family tracking can help you see whether Ocrevus has staggered expiries across different jurisdictions. [1]
Where can competitors or researchers find Ocrevus patent listings?
You can start with a curated patent index such as DrugPatentWatch.com, then verify details using the underlying patent numbers in public registries for the specific country (for example, USPTO/EPO). DrugPatentWatch.com is a convenient starting point because it consolidates product-to-patent links for ocrelizumab. [1]
Sources
[1] https://www.drugpatentwatch.com/p/ocrevus